Head to Head Review: Crispr Theraptc (CRSP) and Exact Sciences Corporation (EXAS)
Crispr Theraptc (NASDAQ: CRSP) and Exact Sciences Corporation (NASDAQ:EXAS) are both biotechnology & medical research – nec companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and profitability.
Insider and Institutional Ownership
25.5% of Crispr Theraptc shares are held by institutional investors. Comparatively, 85.4% of Exact Sciences Corporation shares are held by institutional investors. 40.0% of Crispr Theraptc shares are held by company insiders. Comparatively, 4.0% of Exact Sciences Corporation shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
This table compares Crispr Theraptc and Exact Sciences Corporation’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Exact Sciences Corporation||-60.71%||-30.32%||-27.37%|
Valuation & Earnings
This table compares Crispr Theraptc and Exact Sciences Corporation’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Crispr Theraptc||$5.16 million||147.41||-$23.17 million||($0.07)||-267.71|
|Exact Sciences Corporation||$99.38 million||70.21||-$167.21 million||($1.15)||-50.68|
Crispr Theraptc has higher revenue, but lower earnings than Exact Sciences Corporation. Crispr Theraptc is trading at a lower price-to-earnings ratio than Exact Sciences Corporation, indicating that it is currently the more affordable of the two stocks.
This is a summary of current ratings and price targets for Crispr Theraptc and Exact Sciences Corporation, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Exact Sciences Corporation||0||4||9||0||2.69|
Crispr Theraptc presently has a consensus price target of $23.08, indicating a potential upside of 23.18%. Exact Sciences Corporation has a consensus price target of $50.46, indicating a potential downside of 13.42%. Given Crispr Theraptc’s higher probable upside, analysts plainly believe Crispr Theraptc is more favorable than Exact Sciences Corporation.
Crispr Theraptc Company Profile
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell. The location at which the Cas9 molecular scissors cut the DNA to be edited is specified by guide ribonucleic acid (RNA), which is comprised of a crRNA component and a tracrRNA component, either individually or combined together as a single guide RNA. The Company has business operations in London, the United Kingdom, as well as research and development operations in Cambridge, the United States.
Exact Sciences Corporation Company Profile
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Cologuard test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It focuses on the development of additional tests for other types of cancer. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a computerized tomography (CT) or other scan.
Receive News & Ratings for Crispr Theraptc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Theraptc and related companies with MarketBeat.com's FREE daily email newsletter.